Central sensitization reduces the satisfaction of patients with rheumatoid arthritis. The data of prospective study

Central sensitization (CS) is a pathophysiological phenomenon that plays a fundamental role in the development of chronic pain and fibromyalgia. The presence of CS can significantly worsen the condition of patients with rheumatoid arthritis (RA) and reduce the response to antirheumatic therapy.The a...

Full description

Saved in:
Bibliographic Details
Main Authors: A. S. Potapova, A. E. Karateev, E. Yu. Polishchuk, P. A. Sholkina, E. S. Filatova, V. N. Amirjanova, A. M. Lila
Format: Article
Language:Russian
Published: IMA PRESS LLC 2024-11-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/3640
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849687922876350464
author A. S. Potapova
A. E. Karateev
E. Yu. Polishchuk
P. A. Sholkina
E. S. Filatova
V. N. Amirjanova
A. M. Lila
author_facet A. S. Potapova
A. E. Karateev
E. Yu. Polishchuk
P. A. Sholkina
E. S. Filatova
V. N. Amirjanova
A. M. Lila
author_sort A. S. Potapova
collection DOAJ
description Central sensitization (CS) is a pathophysiological phenomenon that plays a fundamental role in the development of chronic pain and fibromyalgia. The presence of CS can significantly worsen the condition of patients with rheumatoid arthritis (RA) and reduce the response to antirheumatic therapy.The aim of the study – to evaluate the effect of central sensitization on satisfaction in patients with rheumatoid arthritis.Material and methods. The study group consisted of 521 patients with a reliable diagnosis of RA (ACR/EULAR (American College of Rheumatology / European Alliance of Associations for Rheumatology) 2010 criteria), 82.3% of women, 52.0±14.3 years old, with moderate and high disease activity (DAS28-CRP (Disease Activity Score with C-reactive protein) – 4.7±1.0), observed at the clinic of the V.A. Nasonova Research Institute of Rheumatology in 2021– 2022. During hospitalization, all patients underwent correction of the individual therapeutic regimen. At the time of discharge, therapy with genetically engineered biologic DMARDs or Janus kinase inhibitors (JAKi) was continued, induced or modified in 364 patients (69.8%). The presence of a CS was determined by the CSI (Central Sensitisation Inventory) and painDETECT questionnaires. Satisfaction with their condition was assessed during a telephone survey using the PASS index (patient acceptable symptom state) 6 months after discharge from the hospital.Results. Signs of CS according to the CSI questionnaire (≥40 points) were noted in 56.0%, according to the pain- DETECT questionnaire (>18 points) – in 22.5% of patients. A telephone survey was conducted after 6 months in 473 patients (90.8%). 52.0% of respondents considered their condition acceptable (PASS “+”). PASS “+” was significantly more common in patients receiving biologic DMARDs or JAKi, compared with those receiving only synthetic (s) DMARDs: 65.0% and 33.6% (p<0.001). In patients with signs of CS according to CSI, the PASS index “+” was noted in 41.7%, without signs of CS in 65.0% (p<0.001), with signs of CS according to painDETECT, the PASS index “+” was noted in 40.6%, without signs of CS in 55.6% (p<0.001). A significantly lower frequency of PASS “+” was observed in patients with CS both on the background of taking biologic DMARDs or JAKi, and on the background of taking only sDMARDs.
format Article
id doaj-art-0aa4ca4d684c49619010f3be6e6e6c2c
institution DOAJ
issn 1995-4484
1995-4492
language Russian
publishDate 2024-11-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj-art-0aa4ca4d684c49619010f3be6e6e6c2c2025-08-20T03:22:12ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922024-11-0162553554110.47360/1995-4484-2024-535-5413023Central sensitization reduces the satisfaction of patients with rheumatoid arthritis. The data of prospective studyA. S. Potapova0A. E. Karateev1E. Yu. Polishchuk2P. A. Sholkina3E. S. Filatova4V. N. Amirjanova5A. M. Lila6V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationCentral sensitization (CS) is a pathophysiological phenomenon that plays a fundamental role in the development of chronic pain and fibromyalgia. The presence of CS can significantly worsen the condition of patients with rheumatoid arthritis (RA) and reduce the response to antirheumatic therapy.The aim of the study – to evaluate the effect of central sensitization on satisfaction in patients with rheumatoid arthritis.Material and methods. The study group consisted of 521 patients with a reliable diagnosis of RA (ACR/EULAR (American College of Rheumatology / European Alliance of Associations for Rheumatology) 2010 criteria), 82.3% of women, 52.0±14.3 years old, with moderate and high disease activity (DAS28-CRP (Disease Activity Score with C-reactive protein) – 4.7±1.0), observed at the clinic of the V.A. Nasonova Research Institute of Rheumatology in 2021– 2022. During hospitalization, all patients underwent correction of the individual therapeutic regimen. At the time of discharge, therapy with genetically engineered biologic DMARDs or Janus kinase inhibitors (JAKi) was continued, induced or modified in 364 patients (69.8%). The presence of a CS was determined by the CSI (Central Sensitisation Inventory) and painDETECT questionnaires. Satisfaction with their condition was assessed during a telephone survey using the PASS index (patient acceptable symptom state) 6 months after discharge from the hospital.Results. Signs of CS according to the CSI questionnaire (≥40 points) were noted in 56.0%, according to the pain- DETECT questionnaire (>18 points) – in 22.5% of patients. A telephone survey was conducted after 6 months in 473 patients (90.8%). 52.0% of respondents considered their condition acceptable (PASS “+”). PASS “+” was significantly more common in patients receiving biologic DMARDs or JAKi, compared with those receiving only synthetic (s) DMARDs: 65.0% and 33.6% (p<0.001). In patients with signs of CS according to CSI, the PASS index “+” was noted in 41.7%, without signs of CS in 65.0% (p<0.001), with signs of CS according to painDETECT, the PASS index “+” was noted in 40.6%, without signs of CS in 55.6% (p<0.001). A significantly lower frequency of PASS “+” was observed in patients with CS both on the background of taking biologic DMARDs or JAKi, and on the background of taking only sDMARDs.https://rsp.mediar-press.net/rsp/article/view/3640rheumatoid arthritissatisfactionpasscentral sensitizationcsipaindetectbiologic dmardsjak inhibitorsdmards
spellingShingle A. S. Potapova
A. E. Karateev
E. Yu. Polishchuk
P. A. Sholkina
E. S. Filatova
V. N. Amirjanova
A. M. Lila
Central sensitization reduces the satisfaction of patients with rheumatoid arthritis. The data of prospective study
Научно-практическая ревматология
rheumatoid arthritis
satisfaction
pass
central sensitization
csi
paindetect
biologic dmards
jak inhibitors
dmards
title Central sensitization reduces the satisfaction of patients with rheumatoid arthritis. The data of prospective study
title_full Central sensitization reduces the satisfaction of patients with rheumatoid arthritis. The data of prospective study
title_fullStr Central sensitization reduces the satisfaction of patients with rheumatoid arthritis. The data of prospective study
title_full_unstemmed Central sensitization reduces the satisfaction of patients with rheumatoid arthritis. The data of prospective study
title_short Central sensitization reduces the satisfaction of patients with rheumatoid arthritis. The data of prospective study
title_sort central sensitization reduces the satisfaction of patients with rheumatoid arthritis the data of prospective study
topic rheumatoid arthritis
satisfaction
pass
central sensitization
csi
paindetect
biologic dmards
jak inhibitors
dmards
url https://rsp.mediar-press.net/rsp/article/view/3640
work_keys_str_mv AT aspotapova centralsensitizationreducesthesatisfactionofpatientswithrheumatoidarthritisthedataofprospectivestudy
AT aekarateev centralsensitizationreducesthesatisfactionofpatientswithrheumatoidarthritisthedataofprospectivestudy
AT eyupolishchuk centralsensitizationreducesthesatisfactionofpatientswithrheumatoidarthritisthedataofprospectivestudy
AT pasholkina centralsensitizationreducesthesatisfactionofpatientswithrheumatoidarthritisthedataofprospectivestudy
AT esfilatova centralsensitizationreducesthesatisfactionofpatientswithrheumatoidarthritisthedataofprospectivestudy
AT vnamirjanova centralsensitizationreducesthesatisfactionofpatientswithrheumatoidarthritisthedataofprospectivestudy
AT amlila centralsensitizationreducesthesatisfactionofpatientswithrheumatoidarthritisthedataofprospectivestudy